Home > Publications database > Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia. > print

001     124287
005     20240228145504.0
024 7 _ |a 10.1038/bcj.2017.45
|2 doi
024 7 _ |a pmid:28548643
|2 pmid
024 7 _ |a altmetric:20582729
|2 altmetric
037 _ _ |a DKFZ-2017-01183
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Jaramillo, S.
|b 0
245 _ _ |a Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia.
260 _ _ |a London [u.a.]
|c 2017
|b Nature Publishing Group
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1510734762_15361
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a The aim of this cohort study was to compare a condensed schedule of consolidation therapy with high-dose cytarabine on days 1, 2 and 3 (HDAC-123) with the HDAC schedule given on days 1, 3 and 5 (HDAC-135) as well as to evaluate the prophylactic use of pegfilgrastim after chemotherapy in younger patients with acute myeloid leukemia in first complete remission. One hundred and seventy-six patients were treated with HDAC-135 and 392 patients with HDAC-123 with prophylactic pegfilgrastim at days 10 and 8, respectively, in the AMLSG 07-04 and the German AML Intergroup protocol. Time from start to chemotherapy until hematologic recovery with white blood cells >1.0 G/l and neutrophils >0.5 G/l was in median 4 days shorter in patients receiving HDAC-123 compared with HDAC-135 (P<0.0001, each), and further reduced by 2 days (P<0.0001) by pegfilgrastim. Rates of infections were reduced by HDAC-123 (P<0.0001) and pegfilgrastim (P=0.002). Days in hospital and platelet transfusions were significantly reduced by HDAC-123 compared with HDAC-135. Survival was neither affected by HDAC-123 versus HDAC-135 nor by pegfilgrastim. In conclusion, consolidation therapy with HDAC-123 leads to faster hematologic recovery and less infections, platelet transfusions as well as days in hospital without affecting survival.
536 _ _ |a 317 - Translational cancer research (POF3-317)
|0 G:(DE-HGF)POF3-317
|c POF3-317
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Benner, A.
|0 P:(DE-He78)e15dfa1260625c69d6690a197392a994
|b 1
|u dkfz
700 1 _ |a Krauter, J.
|b 2
700 1 _ |a Martin, H.
|b 3
700 1 _ |a Kindler, T.
|b 4
700 1 _ |a Bentz, M.
|b 5
700 1 _ |a Salih, H. R.
|b 6
700 1 _ |a Held, G.
|b 7
700 1 _ |a Köhne, C-H
|b 8
700 1 _ |a Götze, K.
|b 9
700 1 _ |a Lübbert, M.
|b 10
700 1 _ |a Kündgen, A.
|b 11
700 1 _ |a Brossart, P.
|b 12
700 1 _ |a Wattad, M.
|b 13
700 1 _ |a Salwender, H.
|b 14
700 1 _ |a Hertenstein, B.
|b 15
700 1 _ |a Nachbaur, D.
|b 16
700 1 _ |a Wulf, G.
|b 17
700 1 _ |a Horst, H-A
|b 18
700 1 _ |a Kirchen, H.
|b 19
700 1 _ |a Fiedler, W.
|b 20
700 1 _ |a Raghavachar, A.
|b 21
700 1 _ |a Russ, G.
|b 22
700 1 _ |a Kremers, S.
|b 23
700 1 _ |a Koller, E.
|b 24
700 1 _ |a Runde, V.
|b 25
700 1 _ |a Heil, G.
|b 26
700 1 _ |a Weber, D.
|b 27
700 1 _ |a Göhring, G.
|b 28
700 1 _ |a Döhner, K.
|b 29
700 1 _ |a Ganser, A.
|b 30
700 1 _ |a Döhner, H.
|b 31
700 1 _ |a Schlenk, Richard
|0 P:(DE-He78)d8a0e60e5e095f3161ee0de3712409bc
|b 32
|e Last author
|u dkfz
773 _ _ |a 10.1038/bcj.2017.45
|g Vol. 7, no. 5, p. e564 -
|0 PERI:(DE-600)2600560-8
|n 5
|p e564 -
|t Blood cancer journal
|v 7
|y 2017
|x 2044-5385
909 C O |o oai:inrepo02.dkfz.de:124287
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)e15dfa1260625c69d6690a197392a994
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 32
|6 P:(DE-He78)d8a0e60e5e095f3161ee0de3712409bc
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-317
|2 G:(DE-HGF)POF3-300
|v Translational cancer research
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2017
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b BLOOD CANCER J : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
920 1 _ |0 I:(DE-He78)C060-20160331
|k C060
|l Biostatistik
|x 0
920 1 _ |0 I:(DE-He78)G040-20160331
|k G040
|l Klinische Studienzentrale
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C060-20160331
980 _ _ |a I:(DE-He78)G040-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21